FLII and cancer: This suggests a possible interplay between Flii and Flap-1 during cSCC development, as Flap-1 is a naturally occurring antagonist of Flii previously shown to promote asymmetric cancer cell division [37] and regulate epithelial–mesenchymal transition in aggressive metastatic cSCC [23].